''For companies for whom a secondary listing on NYSE or NASDAQ makes no sense, we provide the platform for that trading facility''.
''There's a lack of information out there [about the OTC]'', he says.
''There's just an assumption that having exposure in the US puts you on the hook for an awful lot of additional cost and complexity''.
''When people think about the US, the knee-jerk response is that it's going to cost a lot of money''.
0 Comments